AMGEN- Launched Products + Geographical Expansion Should Sustain the Growth Momentum
We expect Amgen (AMGN) to strengthen further from executing its near term strategy of – (i) optimizing sales force, (ii) expand direct-to-customer (DTC) advertising, and (iii) assuring appropriate access of the products in the US. In the long term, we are optimistic about the potential of its pipeline, strategy to tap the emerging market, and Biosimilars opportunity. AMGN is trading below the NPV of its marketed products + net debt ($92.0/s) and in light of upcoming catalysts, we believe… For more details on pipeline products, please read our report released on 8th Nov. 2012, titled, “Amgen - Launched Products + Geographical Expansion Should Sustain the Growth Momentum”.
